跳转至内容
Merck
CN

HANG2MAG-12K

MILLIPLEX® 人血管生成板2，HANG2MAG-12K

Configurable Human Angiogenesis 19-Plex Panel 2

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MILLIPLEX® 人血管生成板2，HANG2MAG-12K, Configurable Human Angiogenesis 19-Plex Panel 2

species reactivity

human

manufacturer/tradename

Milliplex®

Quality Level

200

packaging

1 ea of

assay range

accuracy: 88-97%
standard curve range: 137-100,000 pg/mL
(Thrombospondin-2)
standard curve range: 137-100,000 pg/mL
(sVEGFR2)
standard curve range: 137-100,000 pg/mL
(suPAR)
standard curve range: 14-10,000 pg/mL
(sAXL)
standard curve range: 14-10,000 pg/mL
(sHER3)
standard curve range: 14-10,000 pg/mL
(sVEGFR1)
standard curve range: 27-20,000 pg/mL
(sIL-6Rα)
standard curve range: 27-20,000 pg/mL
(sPECAM-1)
standard curve range: 27-20,000 pg/mL
(sTIE-2)
standard curve range: 274-200,000 pg/mL
(Angiostatin)
standard curve range: 274-200,000 pg/mL
(sE-Selectin)
standard curve range: 274-200,000 pg/mL
(sNeuropilin-1)
standard curve range: 41-30,000 pg/mL
(Osteopontin (OPN))
standard curve range: 41-30,000 pg/mL
(sEGFR)
standard curve range: 41-30,000 pg/mL
(sHER2)
standard curve range: 41-30,000 pg/mL
(sc-Kit/sSCFR)
standard curve range: 412-300,000 pg/mL
(sVEGFR3)
standard curve range: 69-50,000 pg/mL
(sHGFR)
standard curve range: 7-5,000 pg/mL
(PDGF-AB/BB)

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

相关类别

Features and Benefits

通过在此面板中选择可用的分析物来设计多重试剂盒。

General description

血管生成是新血管网的发展，是正常生长和发育以及伤口愈合的关键过程，其动态平衡由血管生成因子和抑制剂的精细平衡维持。因此，血管生长不足或过度是许多疾病的基础，包括心血管疾病，糖尿病溃疡，黄斑变性和癌症。血管生成在肿瘤生长和转移中起着重要作用。

MILLIPLEX®人体血管生成磁珠面板2是一种20重试剂盒，用于同时定量血清，血浆，细胞培养样品和组织匀浆/裂解物中以下分析物的任何或全部：血管抑素、可溶性E-选择素（sE-Selectin）、骨桥蛋白（OPN）、血小板衍生生长因子-AB/BB（PDGF-AB/BB），可溶性血小板内皮细胞粘连分子-1（sPECAM-1）、血小板反应蛋白-2（TSP-2）、可溶性AXL（sAXL），可溶性c-kit/干细胞生长因子受体（sc-Kit/SCFR），可溶性表皮生长因子受体（sEGFR）†，可溶性人表皮生长因子受体2（sHer2），可溶性人表皮生长因子受体3（sHer3），可溶性肝细胞生长因子受体/c-Met（sHGFR/c-Met），可溶性IL-6Rα，可溶性神经纤毛蛋白1（sNRP-1），可溶性Tie-2（sTie-2），可溶性尿激酶型纤溶酶原激活剂受体（suPAR），可溶性血管内皮生长因子受体1（sVEGFR1），可溶性血管内皮生长因子受体2（sVEGFR2）和可溶性血管内皮生长因子受体3（sVEGFR3）。该试剂盒采用96孔格式，包含冻干标准混合物、两个内部检测质控品，可最多可测定38份样品，重复两次。

†针对活性位点的抗体导致优先结合未结合的EGFR。

Luminex® xMAP®平台使用磁珠免疫分析格式，以实现理想的速度和灵敏度，同时定量多种分析物，从而显著提高生产力，同时节省宝贵的样品量。

面板类型：循环癌症
Angiogenesis, the development of new vascular networks, is a key process in normal growth and development as well as in wound healing, with homeostasis maintained by a delicate balance of angiogenic factors and inhibitors. Consequently, insufficient, or excessive blood vessel growth underlies many diseases, including cardiovascular disease, diabetic ulcers, macular degeneration, and cancer. Angiogenesis plays a significant role in tumor growth and metastasis.

Other Notes

灵敏度：有关单个分析物的灵敏度，请参见试剂盒方案。

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 19 analytes in human serum, plasma, and cell culture supernatants.Analytes included: Angiostatin, soluble E-Selectin, (sE-Selectin), Osteopontin (OPN), Platelet Derived Growth Factor-AB/BB (PDGF-AB/BB), soluble Platelet Endothelial Cell Adhesion Molecule-1 (sPECAM-1), Thrombospondin-2 (TSP-2), soluble AXL (sAXL), soluble c-Kit/Stem Cell Growth Factor Receptor (sc-Kit/SCFR), soluble Epidermal Growth Factor Receptor (sEGFR)†, soluble Human Epidermal Growth Factor Receptor 2 (sHer2), soluble Human Epidermal Growth Factor Receptor 3 (sHer3), soluble Hepatocyte Growth Factor Receptor/c-Met (sHGFR/c-Met), soluble IL-6Rα, soluble Neuropilin-1 (sNRP-1), soluble Tie-2 (sTie-2), soluble Urokinase-type Plasminogen Activator Receptor (suPAR), soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1), soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2), and soluble Vascular Endothelial Growth Factor Receptor 3 (sVEGFR3)†Antibody against active site results in preferential binding to unbound EGFR.Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nicos Mitsides et al.
Nephron, 143(4), 234-242 (2019-09-13)
Progressive chronic kidney disease (CKD) inevitably leads to salt and water retention and disturbances in the macro-and microcirculation. We hypothesize that salt and water dysregulation in advanced CKD may be linked to inflammation and microvascular injury pathways. We studied 23
Sayuri Padayachee et al.
Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria, 37(1), 29-34 (2022-08-11)
A dysregulation of angiogenic mediators has been implicated in HIV infection. Inconsistent data exists on highly active antiretroviral therapy (HAART) usage in pregnancy and its association with PE development. In view of the high prevalence of HIV infection and PE
Luka Roškar et al.
Journal of clinical medicine, 10(4) (2021-03-07)
Preoperative determination of the extent of endometrial cancer (EC) would avoid the complications associated with radical surgery. Screening of patients' plasma biomarkers might enable a more precise diagnosis of EC and a tailored treatment approach. This prospective case-control monocentric pilot
Juan Pablo Hinestrosa et al.
Communications medicine, 2, 29-29 (2022-05-24)
Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage

相关内容

Correlation of Angiogenesis Biomarkers with NSCLC | MILLIPLEX® Assays

The angiogenesis pathway is complex with many targets to analyze. Simultaneous quantification of multiple markers, with the MILLIPLEX® Human Angiogenesis/Growth Factor Panel 1, saves valuable resources. See how this panel was used to correlate angiogenesis biomarkers with early metastatic progression in NSCLC.

Multiplex Cancer Assays for Cancer Research| MILLIPLEX® Assays

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Multiplexing Cancer & Metastasis Signaling Pathways | MILLIPLEX® Assays

Learn how multiplexing with MILLIPLEX® multiplex assays can help simplify cancer research by measuring multiple circulating biomarkers at once. Find multiplex panels to analyze JAK-STAT, mTOR, MAPK, SAPK, TGFβ signaling pathways, and more.

Immunoassays for Cosmetics and Personal Care Research

Learn how immunoassays are used in cosmetics and personal care research to discover potential harmful effects of cosmetics products, and assess markers of inflammation, sensitization, aging, and tissue regeneration among others.

查看所有结果

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持